Ipamorelin 15 mg peptide pen
The selective secretagogue, designed to prompt growth hormone release without the cortisol, prolactin and appetite baggage of its predecessors, at fifteen milligrams, pre-filled.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Discreet dispatch within 24 h
- Research use only
Selectivity, as a product
Ipamorelin is the ghrelin-receptor agonist that made the older secretagogues obsolete: the growth hormone response without hexarelin’s hormone spillover or GHRP-6’s hunger. Five residues, one job, engineered restraint, with the design history on the compound page for this pairing.
Solo, it covers protocols that want the ghrelin route alone; most buyers pair it with CJC-1295 for the two-route rationale the combination page explains. Both options sit on this shelf.
| Compound | Ipamorelin |
| Content | 15 mg, pre-filled |
| Target | Ghrelin receptor |
| Purity | ≥ 99% (HPLC) |
| Designed for | Selectivity over early GHRPs |
| WADA | On the prohibited list |
| Category | Research use only |
Pairing with CJC-1295? The combination pen carries both at a better combined price.
Before the Ipamorelin 15 mg peptide pen reaches the bench
The usual pen regimen, cold, dark, dated, fresh needles.
Fifteen milligrams, one click at a time
A secretagogue series is an exercise in consistency, which the format is built to protect.
Anyone weighing whether to buy ipamorelin pen stock is really buying repeatability, and that is what the click format supplies. The dial moves the same fixed step each session, the cartridge carries all fifteen milligrams of the five-residue secretagogue, and nothing is reconstituted between sessions. Because this is the solo pen, it moves a single route, the ghrelin receptor, so a series run on it isolates that one signal cleanly, which is the whole point of choosing solo.
Across a multi-week run the habits stay small: refrigerate the pen between sessions, keep it clear of the freezer, and mark first use on the barrel. Record each session’s clicks next to the lot number, and the log anchors every data point to this cartridge. Fifteen milligrams is a generous solo fill for a long single-route series, and the pen handling page covers the dial-and-needle routine that keeps it repeatable. Wanting the ghrelin and GHRH arms to move together is a different experiment, the one the fixed-ratio combination pen exists for.
What the literature, actually carries
Selectivity is the strong part of this compound’s case; outcomes are the open part.
The best-supported thing about ipamorelin is comparative: designed as a ghrelin-receptor agonist, it was built to prompt growth-hormone release without the cortisol and prolactin rise, or the sharp appetite, that marked hexarelin and GHRP-6. That comparison is traceable through the ipamorelin literature on PubMed. Selectivity is the part the preclinical record actually characterises, and it is why the compound displaced the older secretagogues. What the same record does not carry is a set of controlled human outcomes, the receptor behaviour is described far more thoroughly than any endpoint that might follow from it.
Underneath the class sits a claim about pulsatility: a secretagogue is meant to prompt the body’s own pulsed release rather than flood the system from outside, and ipamorelin is often the clean example cited. Whether that translates into a meaningful difference in results is genuinely unsettled, argued more than demonstrated. Read honestly, the fifteen-milligram pen is a well-characterised tool for a hypothesis that stays open, which is a fair description rather than a selling point.
Routes and combinations
The GHRH partner, alone or combined in one cartridge.
The science behind Ipamorelin
The class history that explains this compound’s existence.
Questions about the Ipamorelin 15 mg peptide pen
Secretagogue-shelf standards.